EdmundKWallerMD

Oncology • Atlanta, GA

Hematologic Oncology

Professor of Hematology & Oncology, Emory University

Join to view full profile

Dr. Waller is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Waller's full profile

Already have an account?

Office
1365 Clifton Rd NE
Atlanta, GA 30322
Phone+1 404-727-4995

Summary

Dr. Edmund Waller is a hematologist oncologist in Atlanta, GA and is affiliated with multiple hospitals in the area, including Emory University Hospital, Emory University Hospital Midtown, and Grady Memorial Hospital. He received his medical degree from Weill Cornell Medical College of Cornell University and his PhD from Rockefeller University. Following clinical training in Medicine and Medical Oncology at Stanford University and working at Becton Dickinson in San Jose, he has been in practice at Emory for 27 years. He manages an active R01 and P01-funded basic science and translational research laboratory. He has founded two biotech start-ups, Cambium Medical Technologies, a clinical stage company developing Elate Ocular to treat ocular GvHD, and Cambium Oncology, a pre-clinical company developing first-in-class antagonists of a novel immune check-point pathway mediated by signaling through the receptor for vasoactive intestinal polypeptide (VIP). He has clinical expertise in hematologic oncology, cancer immunotherapy, CART, and hematopoietic stem cell transplantation for lymphoma, myeloid malignancies, sickle cell anemia and germ cell cancer. .

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1988 - 1993
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1985 - 1988
Weill Cornell MedicineClass of 1985
Rockefeller UniversityPhD, Chemical Biology, 1978 - 1984
Harvard UniversityAB, Biology, Magna Cum Laude, 1974 - 1978

Certifications & Licensure

CA State Medical License 1987 - Present
GA State Medical License 1995 - 2025
TX State Medical License 1993 - 1995
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2011-2022
America's Top Doctors for Cancer Castle Connolly, 2011-2022

Clinical Trials

Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
Completed
Phase 3
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Start of enrollment: 2006 Nov 01
Completed
Phase 3
A Randomized Study of the Site for Growth Factor Injection for Patients Undergoing Autologous Stem Cell Transplantation Start of enrollment: 2008 Apr 01
Terminated
Phase 2
Stem Cell Related Donor Safety Study Start of enrollment: 2010 Jan 01
Completed
Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection Start of enrollment: 2010 Mar 01
Completed
Phase 2
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Selecting a Favorable KIR Donor in Unrelated HCT for AML Start of enrollment: 2011 Jun 01
Completed
Not Applicable
Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) Start of enrollment: 2011 Jun 01
Terminated
Phase 3
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases Start of enrollment: 2011 Sep 01
Completed
Phase 2
Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease Start of enrollment: 2012 Mar 01
Completed
Phase 2
The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies. Start of enrollment: 2012 Jul 01
Terminated
Phase 2
Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation Start of enrollment: 2013 Dec 01
Withdrawn
Phase 2
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs Start of enrollment: 2014 Jul 01
Terminated
Phase 2
Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation
No longer available
Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients Start of enrollment: 2015 Jul 29
Completed
Phase 2
Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination Start of enrollment: 2015 Dec 23
Terminated
Phase 4
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission Start of enrollment: 2017 Jun 01
Recruiting
Phase 2
Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease Start of enrollment: 2018 May 01
Completed
Phase 1, Phase 2
A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin Start of enrollment: 2020 Oct 27
Completed
Phase 2
Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19) Start of enrollment: 2020 Nov 18
Completed
Phase 2
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study Start of enrollment: 2022 Jan 13
Recruiting
Early Phase 1
STRIDE Biorepository Start of enrollment: 2017 Mar 13
Recruiting
Roles: Contact
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) Start of enrollment: 2022 Jun 16
Terminated
Phase 3
Roles: Contact
A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001) Start of enrollment: 2022 Jul 12
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Bone Marrow and Peripheral Blood Immune Responses Study Start of enrollment: 2023 Oct 16
Recruiting
Phase 4
Roles: Contact, Principal Investigator
Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy Start of enrollment: 2023 Mar 31
Active, not recruiting
Phase 2
Roles: Contact
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT Start of enrollment: 2022 Jun 16
Recruiting
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

118 citations
Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T-Cell Mediated Apoptosis Which Is Partly Rescued by IFNγ Licensing.
Raghavan Chinnadurai, Ian B. Copland, Marco Garcia, Christopher T. Petersen, Christopher N. Lewis
Stem Cells. 2016-09-01
297 citations
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
Sally Arai, Mukta Arora, Tao Wang, Stephen R. Spellman, Wensheng He
Biology of Blood and Marrow Transplantation. 2015-02-01
2 citations
Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study.
Philip L McCarthy, Kristopher M Attwood, Xiaojun Liu, George L Chen, Hans Minderman
Bone Marrow Transplantation. 2024-03-01

Journal Articles

The Potential of CAR T Cell Therapy in Pancreatic Cancer
Mehmet Akce, Mohammad Y Zaidi, Edmund K Waller, Frontiers in Neurology
Recipient Single Nucleotide Polymorphisms in Paneth Cell Antimicrobial Peptide Genes and Acute Graft‐Versus‐Host Disease: Analysis of BMT CTN‐0201 and ‐0901 Samples
Armin Rashidi, Edmund K Waller, Bharat Thyagarajan, Claudio Anasetti, Daniel J Weisdorf, Bart L Scott, Bruce R Blazar, British Journal of Haematology
Indoles Derived from Intestinal Microbiota Act via Type I Interferon Signaling to Limit Graft-Versus-Host-Disease
Edmund K Waller, Zachariah DeFilipp, Muna Qayed, Akshay Sharma, Blood

Abstracts/Posters

Outcomes of Elderly Patients Undergoing Allogeneic Transplantation for Acute Myeloid Leukemia with Fludarabine/Melphalan or Fludarabine/TBI Conditioning Regimen
Edmund K. Waller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizu...
Edmund K. Waller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
IMPACT-TB*: A Phase II Trial Assessing the Capacity of Low Dose Imatinib to Induce Myelopoiesis and Enhance Host Anti-Microbial Immunity Against Tuberculosis. *Imatini...
Edmund K. Waller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B...
Edmund K. Waller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...
Edmund K. Waller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase II Trial to Compare Allogeneic Transplant Vs. Standard of Care for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Pr...
Edmund K. Waller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagen...
Edmund K. Waller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic MalignanciesDecember 2023

Press Mentions

Research Roundup: Recent Grants and Publications for Emory Faculty and StaffMarch 10th, 2022
Research Roundup: Recent Grants and Publications for Emory Faculty and StaffSeptember 21st, 2021
NIAID Supports Clinical Testing of Anti-Cancer Drug for TBAugust 15th, 2017
Join now to see all

Grant Support

Using donor dendritic cells to optimize GvHD and GvL in allogeneic stem cell transplantationNIH/NCI/NHLBI2020–2025
Development of Gleevec for TB and TB/HIVNIH/NIAID2015–2022
Modified Donor Lymphocytes Infusion (MDLI) For Rapid Immune ReconstitutionNational Heart, Lung, And Blood Institute2011
Immunologic And Virologic Monitoring Laboratory CoreNational Heart, Lung, And Blood Institute2011
Clinical Trials- Shared ResourcesNational Cancer Institute2009–2011
Separating Antitumor &Gvhd In Allogeneic T-CellsNational Cancer Institute2003–2007
Adoptive Transfer Of Immunity In Bone Marrow TransplantationNational Center For Research Resources1999–2002
Antileukemic Effect Of Irradiated Allogeneic LymphocytesNational Cancer Institute1998–2000